The present analysis revealed that tumor PD‐L1 was not associated with prognostic outcomes of patients with GBM treated with immunotherapy and did not predict a better outcome following immunotherapy over control therapy, suggesting the limited predictive value of tumor PD‐L1 expression. This evidence concerns the gene CD274 and glioblastoma.